Interaction between 5-HT1A and nicotinic cholinergic receptors in the regulation of water maze navigation behavior

Riekkinen, Minna; Tolonen, R; Riekkinen, Paavo

doi:10.1016/0006-8993(94)91061-8

Cited by 27 publications

(13 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two mec doses tested in our study are significantly lower than those used in most studies of the effects of mec on learning in the MWM. Doses as low as 2.5 mg/kg have been reported to reduce learning in the MWM [Riekkinen et al, 1994], whereas more commonly, higher doses (i.e., 10 mg/kg) have been used [Decker and Majchrzak, 1992;Riekkinen et al, 1992].…”

Section: Spatial Memorymentioning

confidence: 98%

Dose‐specific improvements in memory‐related task performance by rats and aged monkeys administered the nicotinic‐cholinergic antagonist mecamylamine

Terry

Buccafusco

Prendergast

1999

Drug Development Research

View full text Add to dashboard Cite

Section: Spatial Memorymentioning

confidence: 98%

Dose‐specific improvements in memory‐related task performance by rats and aged monkeys administered the nicotinic‐cholinergic antagonist mecamylamine

Terry

Buccafusco

Prendergast

1999

Drug Development Research

View full text Add to dashboard Cite

“…It has been suggested that other neurotransmitter systems are involved such as the glutamatergic and serotonergic systems [210]. Abnormalities in monoaminergic systems have been reported in AD patients [211,212] and AD patients have lower levels of the neurotransmitter serotonin (5-HT) and its metabolites [213,214]. Accumulating evidence emphasizes the positive role that serotonin plays in cognitive function [215].…”

Section: Clinical Studies Of Antidepressants On Cognitive Functionmentioning

confidence: 99%

Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease

Aboukhatwa

Dosanjh

Luo

2010

Mol Neurodegeneration

View full text Add to dashboard Cite

There is a high prevalence rate (30-50%) of Alzheimer's disease (AD) and depression comorbidity. Depression can be a risk factor for the development of AD or it can be developed secondary to the neurodegenerative process. There are numerous documented diagnosis and treatment challenges for the patients who suffer comorbidity between these two diseases. Meta analysis studies have provided evidence for the safety and efficacy of antidepressants in treatment of depression in AD patients. Preclinical and clinical studies show the positive role of chronic administration of selective serotonin reuptake inhibitor (SSRI) antidepressants in hindering the progression of the AD and improving patient performance. A number of clinical studies suggest a beneficial role of combinatorial therapies that pair antidepressants with FDA approved AD drugs. Preclinical studies also demonstrate a favorable effect of natural antidepressants for AD patients. Based on the preclinical studies there are a number of plausible antidepressants effects that may modulate the progression of AD. These effects include an increase in neurogenesis, improvement in learning and memory, elevation in the levels of neurotrophic factors and pCREB and a reduction of amyloid peptide burden. Based on this preclinical and clinical evidence, antidepressants represent a rational complimentary strategy for the treatment of AD patients with depression comorbidity.

show abstract

“…Dysregulation of 5-HT function is believed to be involved in depression, impulsivity, and suicide (Arango et al 1992;Kennett 1991;Meltzer 1990;Staner et al 1992). Additionally, modulation of cholinergic neuronal activity by 5-HT may play a role in higher cognitive processes such as memory and learning (Altman et al 1990;Carli et al 1992;RichterLevin and Segal 1990;Riekkinen et al 1994). Accordingly, alterations in serotonergic function may account for behavioral disturbances commonly observed in the elderly.…”

Section: Anatomy Of the Serotonin Systemmentioning

confidence: 99%

“…18, NO. 6 learning (Altman et al 1990; Carli et al 1992; RichterLevin and Segal 1990;Riekkinen et al 1994). Accordingly, alterations in serotonergic function may account for behavioral disturbances commonly observed in the elderly.…”

Section: Anatomy Of the Serotonin Systemmentioning

confidence: 99%

Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging

Meltzer

Smith

DeKosky

et al. 1998

Neuropsychopharmacology

464

240

View full text Add to dashboard Cite

(5-HT) neuron and neurotransmitter loss in normal aging and neuropsychiatric diseases of late life may contribute to behavioral changes commonly observed in the elderly population. Extensive evidence implicates a deficit in serotonergic neurotransmission in the development of major depression. It has been further suggested that the agerelated changes in 5-HT neurons may predispose the elderly to develop depression. There is also increasing evidence that a combination of disturbances in cholinergic and serotonergic function may play a role in cognitive impairment in Alzheimer's disease (AD), with serotonergic dysfunction potentially responsible for a significant portion of the behavioral aspects of the disease. This implication of the 5-HT system in aging and age-related cognitive and mood disorders rests in large part on post mortem studies and animal models, which are limited in their capacity to predict dynamic human biochemical-behavior relationships or to accurately model the living human brain. Initial applications of functional brian imaging with positron emission tomography (PET) in the in vivo study of the brain in aging, depression, and dementia focused on characterizing alterations in physiological measurements of cerebral metabolism and perfusion. However, recent advances in PET radiochemistry, instrumentation, and image processing have paved the way for noninvasive means to test specific hypotheses regarding the direct involvement of 5-HT neurons in the behavioralMajor depression in late life and Alzheimer's disease (AD) are disorders of enormous and increasing public health significance. The prevalence of major depression is estimated at 1% to 10% of persons 60 years of age or older, whereas depressive symptoms may occur in up to 20% (Blazer et al. 1987; Borson et al. 1986; Casey 1994). Substantially higher rates of both major and minor depressions occur among institutionalized aged persons (Parmelee et al. 1989). Furthermore, the rate of suicide in this age group is higher than at any other Address correspondence to: Carolyn Cidis Meltzer, M.D., University of Pittsburgh Medical Center, PET Facility, B-938, 200 Lothrop Street, Pittsburgh, PA 15213-2582. Received March 6, 1997 accepted October 3, 1997. 408 C.C. Meltzer et al.N EUROPSYCHOPHARMACOLOGY 1998 -VOL . 18 , NO . 6 stage of life (Casey 1994). Psychosocial issues such as bereavement, disability, and declining health may serve as contributing factors in the development of geriatric depression (Casey 1994;Gilewski et al. 1991;Kennedy et al. 1991). Ad is truly a disorder of aging, with an incidence of 5% in persons older than 65 years and doubling of disease prevalence every 5 years after age 65; affected individuals represent 20% to 50% of the population after age 80 (Cross and Gurland 1986) (Evans et al. 1989). Costs associated with dementia burden exceed $90 billion annually in the United States (Ernst and Hay 1994). Depression is commonly seen in AD patients and may further interfere with cognitive function, as well as substantially...

show abstract

Interaction between 5-HT1A and nicotinic cholinergic receptors in the regulation of water maze navigation behavior

Cited by 27 publications

References 66 publications

Dose‐specific improvements in memory‐related task performance by rats and aged monkeys administered the nicotinic‐cholinergic antagonist mecamylamine

Dose‐specific improvements in memory‐related task performance by rats and aged monkeys administered the nicotinic‐cholinergic antagonist mecamylamine

Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease

Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging

Contact Info

Product

Resources

About